Scottish Medicines Consortium completes its initial assessment of evidence for the volanesorsen (Waylivra) using ultra orphan framework (UOF)

From 16 Nov 2020, this can be prescribed within UOF as adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

SPS commentary:

After 3 years the company will provide an updated submission for reassessment to allow a decision on its routine use in NHS Scotland.


Scottish Medicines Consortium